ArticleNanomedicine (London, England)2015
Clinically applicable magnetic-labeling of natural killer cells for MRI of transcatheter delivery to liver tumors: preclinical validation for clinical translation.
Article in Nanomedicine (London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
- Functional Repurposing of Magnetic Nanoparticle-Assisted Hyperthermia for Immune Cell Labelling and Tracking.Small methods · 2026Article
- A Comparison of the Sensitivity and Cellular Detection Capabilities of Magnetic Particle Imaging and Bioluminescence Imaging.Tomography (Ann Arbor, Mich.) · 2024Article
- Application of magnetic nanoparticles in adoptive cell therapy of cancer; training, guiding and imaging cells.Nanomedicine (London, England) · 2024Review
- Options for imaging cellular therapeutics in vivo: a multi-stakeholder perspective.Cytotherapy · 2021Review
- Iron oxide nanoparticles for immune cell labeling and cancer immunotherapy.Nanoscale horizons · 2021Review
- Review
- Immune cell labelling and tracking: implications for adoptive cell transfer therapies.EJNMMI radiopharmacy and chemistry · 2021Review
- A dual-modal PET/near infrared fluorescent nanotag for long-term immune cell tracking.Biomaterials · 2021Article
- HSP70/IL-2 Treated NK Cells Effectively Cross the Blood Brain Barrier and Target Tumor Cells in a Rat Model of Induced Glioblastoma Multiforme (GBM).International journal of molecular sciences · 2020Article
- Review
- Immunological effects of iron oxide nanoparticles and iron-based complex drug formulations: Therapeutic benefits, toxicity, mechanistic insights, and translational considerations.Nanomedicine : nanotechnology, biology, and medicine · 2018Review
- Article
- Physicochemical characterization of ferumoxytol, heparin and protamine nanocomplexes for improved magnetic labeling of stem cells.Nanomedicine : nanotechnology, biology, and medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
aimTo test the hypothesis that MRI can monitor intraportal vein (IPV) transcatheter delivery of clinically applicable heparin-protamine-ferumoxytol (HPF) nanocomplex-labeled natural killer (NK) cells to liver tumor. MATERIALS &
methodsLiver tumor rat models underwent catheterization for IPV infusion of HPF-labeled NK cells (NK-92MI cell line). MRI measurements within tumor and adjacent liver tissues were compared pre- and post-NK cell infusion. Histology studies were used to identify NK cells in the target tumors.
resultsFor first time, we demonstrated that MRI tracks HPF-labeled NK cells migration within liver following IPV delivery.
conclusionIPV transcatheter infusion permitted selective delivery of NK cells to liver tissues and MRI allowed tracking NK cell biodistributions within the tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.